研究单位：[1]Capital Medical University Affiliated Beijing Shijitan Hospital[2]Fresenius Kabi Sino-Swed Pharmaceutical Corp. Ltd[3]Beijing Hospital,Beijing,China,100730[4]Beijing Cancer Hospital,Beijing,China[5]Capital Medical University Affiliated Beijing Shijitan Hospital,Beijing,China[6]Peking University People''s Hospital,Beijing,China[7]Xiangya Hospital Central South University,Changsha,China[8]The First Affiliated Hospital Of Guangzhou Medical University,Guangzhou,China[9]Nanfang Hospital,Guanzhou,China[10]Yunnan Cancer Hospital（The affiliated hospital of Kunming medical university）,Kunming,China[11]Jiangsu Province Hospital of Chinese Medicine,Nanjing,China[12]The Affiliated Hospital of Qingdao University,Qingdao,China[13]The Fourth Hospital of Hebei Medical University （Hebei Tumor Hospital）,Shijia Zhuang,China[14]The First Affiliated Hospital of SOOCHOW University,Suzhou,China[15]The Central Hospital of Wuhan,Wuhan,China[16]Union hospital tongji medical college huazhong university of science and technology,Wuhan,China
研究目的：
This is a prospective, randomized, open label, active-controlled, multi-centre, non-inferiority clinical trial. Aim of the study is to evaluate the efficacy and safety of Fresubin Support Drink in patients with gastrointestinal cancer undergoing surgical resection during the perioperative period.
